Risks of Living Donor Liver Transplantation Using Small-For-Size Grafts.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Historique:
received: 04 11 2019
accepted: 10 01 2020
pubmed: 25 5 2020
medline: 1 12 2020
entrez: 25 5 2020
Statut: ppublish

Résumé

In living donor liver transplantation (LDLT), a graft-to-recipient weight ratio (GRWR) of under 0.8 is recognized as the critical graft size. Our aim was to compare the survival rates of recipients with small-for-size grafts (SFSG: GRWR <0.8), normal-sized grafts (NSG), and large-for-size grafts (LFSG: GRWR ≥ 3.5) and to investigate the mortality risk with SFSG. Between 1991 and April 2019, we performed 188 LDLT surgeries. Recently, we added splenectomy when portal vein pressure is high (>17 mm Hg) to interrupt the splenic bloodstream. We divided all LDLT cases retrospectively into 3 groups: an SFSG group (n = 22), NSG group (n = 154), and LFSG group (n = 12). We investigated the survival rates in these groups. Furthermore, we divided the SFSG group into 2 subgroups: an SFSG with splenectomy (SFSG+S) group (n = 7) and an SFSG without splenectomy group. We investigated the occurrence rates of lethal complications such as portal vein thrombosis, hepatic artery thrombosis, and hepatic vein thrombosis. The 5-year survival rate in the SFSG group was significantly lower (52.8%) than in the other groups (NSG: 84.5%; LFSG: 83.3%), but that of the SFSG+S group was similar (80.0%) to that of other groups. There was no difference in the occurrence of postoperative complications such as portal vein thrombosis, hepatic artery thrombosis, or hepatic vein thrombosis between the SFSG+S group and other groups. Graft survival of LDLT using SFSG+S was as good as that of normal-sized grafts. Reducing portal vein pressure was important for SFSG.

Sections du résumé

BACKGROUND BACKGROUND
In living donor liver transplantation (LDLT), a graft-to-recipient weight ratio (GRWR) of under 0.8 is recognized as the critical graft size. Our aim was to compare the survival rates of recipients with small-for-size grafts (SFSG: GRWR <0.8), normal-sized grafts (NSG), and large-for-size grafts (LFSG: GRWR ≥ 3.5) and to investigate the mortality risk with SFSG.
METHODS METHODS
Between 1991 and April 2019, we performed 188 LDLT surgeries. Recently, we added splenectomy when portal vein pressure is high (>17 mm Hg) to interrupt the splenic bloodstream. We divided all LDLT cases retrospectively into 3 groups: an SFSG group (n = 22), NSG group (n = 154), and LFSG group (n = 12). We investigated the survival rates in these groups. Furthermore, we divided the SFSG group into 2 subgroups: an SFSG with splenectomy (SFSG+S) group (n = 7) and an SFSG without splenectomy group. We investigated the occurrence rates of lethal complications such as portal vein thrombosis, hepatic artery thrombosis, and hepatic vein thrombosis.
RESULTS RESULTS
The 5-year survival rate in the SFSG group was significantly lower (52.8%) than in the other groups (NSG: 84.5%; LFSG: 83.3%), but that of the SFSG+S group was similar (80.0%) to that of other groups. There was no difference in the occurrence of postoperative complications such as portal vein thrombosis, hepatic artery thrombosis, or hepatic vein thrombosis between the SFSG+S group and other groups.
CONCLUSIONS CONCLUSIONS
Graft survival of LDLT using SFSG+S was as good as that of normal-sized grafts. Reducing portal vein pressure was important for SFSG.

Identifiants

pubmed: 32446690
pii: S0041-1345(19)31514-3
doi: 10.1016/j.transproceed.2020.01.136
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1825-1828

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Shigehito Miyagi (S)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: msmsmiyagi@yahoo.co.jp.

Yoshihiro Shono (Y)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Kazuaki Tokodai (K)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Wataru Nakanishi (W)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Ryuichi Nishimura (R)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Atsushi Fujio (A)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Kengo Sasaki (K)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yuki Miyazaki (Y)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yuta Kakizaki (Y)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Hideaki Sasajima (H)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Takashi Kamei (T)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Michiaki Unno (M)

Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH